Drugs / BM-MSCs
BM-MSCs
Trials 10 · a red edge is where a trial was stopped
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 01 trial | ||||||
| Phase 0 | NCT03248466 | Aug 2017 → Jan 2020 | ulcer of lower limbs | Third Military Medical University | Unknown | No outcome recorded |
| Phase 13 trials | ||||||
| Phase 1 | NCT04815213 | Jan 2022 → Jan 2025 overdue | primary ovarian failure | University of Jordan | Active not recruiting | No outcome recorded |
| Phase 1 | NCT04410731 | Apr 2020 → Mar 2024 | — | Mayo Clinic | Completed | No outcome recorded |
| Phase 1 | NCT02646007 | Nov 2015 → Nov 2018 | Kienbock disease | Royan Institute | Unknown | No outcome recorded |
| Phase 1/25 trials | ||||||
| Phase 1/2 | NCT04346368 | Apr → Dec 2020 | COVID-19 | Guangzhou Institute of Respiratory Disease | Unknown | No outcome recorded |
| Phase 1/2 | NCT03059355 | Apr 2018 → Mar 2020 | metabolic syndrome X | Joshua M Hare | Terminated | No outcome recorded |
| Phase 1/2 | NCT03397095 | Apr 2018 → Dec 2019 | ischemic disease | Shanghai 10th People's Hospital | Unknown | No outcome recorded |
| Phase 1/2 | NCT02504437 | Nov 2015 → Dec 2017 | acute myocardial infarction, cardiomyopathy | Academy Military Medical Science, China | Unknown | No outcome recorded |
| Phase 1/2 | NCT02449005 | Mar 2014 → Sep 2016 | chronic periodontitis | Aristotle University Of Thessaloniki | Completed | No outcome recorded |
| Phase 21 trial | ||||||
| Phase 2 | NCT07329569 | Mar 2026 → Sep 2029 expected | — | Fondation Ophtalmologique Adolphe de Rothschild | Not yet recruiting | No outcome recorded |
Also used as a comparator or background therapy in 1 trial
| Phase | Registry id | Dates | Indication | Sponsor | Status | Outcome |
|---|---|---|---|---|---|---|
| Phase 2 | NCT06001853 Comparator | Nov 2023 → Dec 2027 expected | osteoarthritis, spine | Mayo Clinic | Active not recruiting | No outcome recorded |
Evidence & citations 7 cited values
Every value below carries the sentence it was read from. 13 sources stand behind the page.
| Field | Value | Cited text |
|---|---|---|
| Known as | BM-MSCs | “allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) administered by subconjunctival injection in patients with severe ocular chemical burns (stage VI according to...” NCT07329569 ↗10“autologous bone marrow derived mesenchymal stromal cells (BM-MSCs) transplantation after core decompression in Kienböck disease” PMID 39290122 ↗ Sep 2024 “Autologous bone marrow-derived mesenchymal cells (BMMSCs), dose 20 million cells/ovary” NCT04815213 ↗ “allogeneic, culture-expanded BM-MSCs” NCT06001853 ↗ |
| Known as | a-BMMSCs | “autologous clinical-grade alveolar bone marrow mesenchymal stem cells (a-BMMSCs), seeded into collagen scaffolds” PMID 33899259 ↗ May 2021 |
| Known as | allogeneic bone marrow-derived mesenchymal stem cells | “allogeneic bone marrow-derived mesenchymal stem cells (BM-MSCs) administered by subconjunctival injection in patients with severe ocular chemical burns (stage VI according to...” NCT07329569 ↗ |
| Known as | bone marrow derived mesenchymal stromal cells | “Intra-articular delivery of allogeneic bone marrow derived mesenchymal stromal cells (BM-MSCs) for painful lumbar facet arthropathy: a phase I clinical trial.” PMID 41163019 ↗ Oct 2025 |
| Known as | bone marrow mesenchymal stem cells | “autologous bone marrow mesenchymal stem cells (BMMSCs) without pre-condition.” NCT02504437 ↗ |
| Modality | Cell therapy | “autologous alveolar bone marrow mesenchymal stem cells” NCT02449005 ↗ |
| Route | Intravenous | “delivered via peripheral intravenous infusion” NCT03059355 ↗ |